$ADMA Shareholder Alert: ADMA Biologics 29% Stock Drop Leads to Securities Fraud Class Action Over Channel Stuffing Claims
Bleichmar Fonti & Auld LLP announced a class action lawsuit against ADMA Biologics regarding alleged securities fraud connected to channel stuffing of its ASCENIV product. The complaint alleges that ADMA reported 20% growth in 2025 by inducing a distributor to stock excess inventory through rebates and extended payment terms, masking an actual 3% revenue decline. Investors have until August 10, 2026, to seek lead plaintiff status in the U.S.
Key figures
- Lead Plaintiff Deadline
- August 10, 2026
- Alleged real growth
- -3%
- Alleged reported growth
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.